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Molecular classiﬁcationGastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the fourth most
common cancer globally, with East Asia accounting for more than half of cases annually. Alongside TNM staging,
gastric cancer clinic has twowell-recognized classiﬁcation systems, the Lauren classiﬁcation that subdivides gas-
tric adenocarcinoma into intestinal and diffuse types and the alternative World Health Organization system that
divides gastric cancer into papillary, tubular, mucinous (colloid), and poorly cohesive carcinomas. Both classiﬁca-
tion systems enable a better understanding of the histogenesis and the biology of gastric cancer yet have a limited
clinical utility in guiding patient therapy due to the molecular heterogeneity of gastric cancer. Unprecedented
whole-genome-scale data have been catalyzing and advancing the molecular subtyping approach. Here we
cataloged and compared those published gene expression proﬁling signatures in gastric cancer. We summarized
recent integrated genomic characterization of gastric cancer based on additional data of somatic mutation, chro-
mosomal instability, EBV virus infection, and DNA methylation. We identiﬁed the consensus patterns across
these signatures and identiﬁed the underlying molecular pathways and biological functions. The identiﬁcation
of molecular subtyping of gastric adenocarcinoma and the development of integrated genomics approaches for
clinical applications such as prediction of clinical intervening emerge as an essential phase toward personalized
medicine in treating gastric cancer.
© 2015 Lin et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
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ehalf of the ResearchNetwork of Com1. Introduction
Gastric cancer (GC) is the second leading cause of cancer death and
the fourth most prevalent malignancy worldwide, accounting for 8% of
cancer incidence and 10% of cancer deaths [1]. In the United States,putational and Structural Biotechnology. This is an open access article under the CC BY license
449X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458about 21,000 cases of gastric cancer (61% are men and 39% are women)
were diagnosed and about 10,000 patients died from this disease in
2012 [2]. Many factors such as ineffective screening, diagnosis, and
treatment approaches contribute to the high incidence and mortality
rates of GC [3,4].
Tumor staging has been established and validated as the best predic-
tor of patient survival. Besides tumor node metastasis (TNM) staging,
gastric cancer clinic has two well-recognized classiﬁcation systems,
the Lauren classiﬁcation that subdivides gastric adenocarcinoma into
intestine and diffuse types and the alternative World Health Organiza-
tion system that divides gastric cancer into papillary, tubular, mucinous
(colloid), and poorly cohesive carcinomas. Both classiﬁcation systems
enable a better understanding of histogenesis and biology of gastric can-
cer yet have a limited clinical utility in guiding patient therapy, especial-
ly when dealing with the molecular heterogeneity of gastric cancer [5,
6]. The TNM classiﬁcation is themost important tool for planning treat-
ment in oncology and for assessing the patient's prognosis. However,
even the latest edition of the TNM classiﬁcation has limited power to
capture the complex cascade of progression events that derived from
the heterogeneous clinical behavior of GC [7].
In the past decade, much progress has been made in identifying
more accurately molecular GC subtypes by gene expression proﬁling
based onmicroarray technologies [8]. Such advances hold a great prom-
ise in improving prognosis and identifying more appropriate therapies
[9]. High-throughput large-scale molecular proﬁling data provide rich
information that is unobtainable from morphological or clinical exami-
nations alone. Unprecedented whole-genome-scale data have been cat-
alyzing and advancing the molecular subtyping approach.
Here we cataloged and compared published gene expression proﬁl-
ing signatures in GC as well as more integrated genomic features of GC
from gene expression, somatic mutation, chromosomal instability, Ep-
stein–Bar Virus (EBV) virus infection, and DNA methylation. We
highlighted the consensus patterns across these signatures, identiﬁed
their associated molecular pathways, and underscored their prediction
power of GC stratiﬁcation and chemotherapy sensitivity. Fig. 1 outlines
the contents of this review which focuses on applications of geneFig. 1. Applications of molecular proﬁling in diagnosis and treatment of GC. The applications of
prognosis evaluation. EGC: early gastric cancer; CUP: cancer of unknown primary site.expression proﬁling in diagnosis, prognosis, and therapeutic interven-
tion of GC.2. Molecular diagnosis of GC
Gene expression signatures have successfully been identiﬁed to de-
termine, differentiate, and categorize subtypes of GC as well as to
solve some diagnostic dilemmas [8]. In early gastric cancer (EGC),
tumor invasion is conﬁned to the mucosa or submucosa regardless of
the presence of lymph node metastasis or not [10]. Gene expression
analysis identiﬁed a signature that differentiated EGC from normal tis-
sue [10]. Boussioutas et al. analyzed 124 tumor and adjacent mucosa
samples and explored the molecular features of gastric cancer, which
could be discerned that readily deﬁned premalignant and tumor sub-
types, using DNA microarray-based gene expression proﬁling [11]. The
identiﬁcation of molecular signatures that are characteristic of subtypes
of gastric cancer and associated premalignant changes should enable
further analysis of the steps involved in the initiation and progression
of gastric cancer. Vecchiet al. derived 1024 genes (52% up-regulated
and 48% down-regulated) that were differentially expressed in 19 EGC
samples when compared with 9 normal tissues [12]. The up-regulated
genes are involved in cell cycle, RNA processing, ribosome biogenesis,
and cytoskeleton organization, while the down-regulation genes are
implicated in speciﬁc functions of the gastric mucosa (digestion, lipid
metabolism, and G-protein-coupled receptor protein signaling path-
way). Nam et al. [13] also identiﬁed a 973-gene signature to differenti-
ate EGC fromnormal tissue using themicroarray data from thematched
tumor and adjacent non-cancerous tissues of 27 EGC patients [13]. They
further demonstrated that the up-regulated genes in EGC tissues were
correlated with cell migration and metastasis. Kim et al. demonstrated
that 60 genes were gradually up or down-regulated in succession in
normal mucosa, adenoma, and carcinoma samples by comparing the
expression proﬁles of these tissues from eight patient-matched sets.
Thus, molecular classiﬁcation seems very promising for molecular diag-
nosis of EGC [14].gene expression proﬁling in GC include diagnosis, subgroup, TNM staging, treatment, and
450 X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458Both chronic gastritis (ChG) and intestinal metaplasia (IM) are
involved in intermediate stage of GC, the former characterized by a
mitochondria-related gene expression signature while the latter char-
acterized by markers of proliferation [11]. Since ChG has mitochondria
gene expression signature, it might be interesting to test whether such
a signature is related to the metabolic subtype signature of GC [15].
Indeed, the differential expressed gene set between ChGand IM is large-
ly overlapped with the GC metabolic signature (P = 0.00085,
hypergeometric test).
Cancer of unknown primary site (CUP) is a well-recognized clinical
disorder, accounting for 3–5% of all malignant epithelial tumors [12].
CUP can be identiﬁed based on conserved tissue-speciﬁc gene expres-
sion [16]. It has been shown that gene expression proﬁling can identify
tissue of origin with an accuracy rate between 33% and 93% [17]. Antho-
ny et al. applied a 92-gene CUP assay to tumor samples from patients
with CUP. Fifteen of 20 cases (75%) were correctly predicted, i.e., those
predicted CUPs were the actual latent primary sites that were identiﬁed
after the initial diagnosis of CUP. This assay has been successfully applied
to many other cancers such as breast, colorectal, and melanoma [18].
These gene signature-based methods can also be used to identify
speciﬁc treatment for GC patients, i.e., targeted therapies. In a large pro-
spective trial (n= 289), a gene expression signature was developed to
predict the tissue of origin in most patients with CUP. The median sur-
vival time was 12.5 months for patients who received assay-directed
site-speciﬁc therapy compared with the use of empiric CUP regimens.
Patients whose CUP sites were predicted to have more responsive
tumor types survived longer than those predicted to have less respon-
sive tumor types [19]. These ﬁndings suggest that tumormolecular pro-
ﬁling can improve the treatment of patients with CUP and should be
included in the standard evaluation [19].
While some great progresses have beenmade onmolecular diagnosis
based ongene expression proﬁling andmanyhospitals havebuilt up facil-
ities for molecular diagnosis, these technologies are still expensive and
immature. Thus, reliable and cost-effective molecular diagnosis tools
based on gene expression signatures have a broad development potential.
3. Molecular subtyping of GC
Histologically, GC shows great heterogeneity at both architectural
and cytological levels and often has several co-existing tissue types
such as well-developed tubular architecture and signet ring cell. TheTable 1
Gene expression proﬁling associated with sensitivity or resistance to anticancer drugs in GC.
Signature Samples Drugs
NA Three sensitive and one resistant GC
cell line
Cisplatin
250 genes Ten chemoresistant and 4 parent GC
cell lines
Cisplatin
13 genes Eight GC cell lines 5-FU
23 genes 35 GC cases 5-FU
69 genes/5 ﬂu and
45 genes/cisplatin
Three GC cell lines 5-FU
39 genes NA 5-FU
119 genes Seven GC cases 5-FU/cisplatin
four genes Three cell lines and 37 GC Paclitaxel
NA 30 cancer cell lines 5-FU
NA 45 cancer lines including 12 GC cell lines 53 drugs
12 genes 19 cell lines and 30 GC 8 drugs
85 genes 13 GC cell lines 16 drugs
seven genes 20 GC cases and 19 GC validation Doxorubicin
MRP4 One GC cell line(SGC7901) Cisplatin
NA Three GC cell lines Parthenolide
NA Three GC cell lines Vorinostat
NA Three GC cell lines Metforminprimary histopathologic classiﬁcation used for GC was ﬁrst described
in 1965 by Lauren [20]. This classiﬁcation simply divides gastric adeno-
carcinomamorphologically into two types: thediffuse and the intestinal
types. The relative frequencies for intestinal, diffuse, and indeterminate
types are approximately 54%, 32%, and 15%, respectively [21]. The intes-
tinal type often hasmorewell-developed tubular architecturewhile the
diffuse type often includes poorly cohesive cells or signet ring cells [22].
Moreover, the diffuse type gastric cancer tends to carry germlinemuta-
tions in genes involved in the cell adhesion protein E-cadherin; in con-
trast, the intestinal type is associated with atrophic gastritis, intestinal
metaplasia, and Helicobacter pylori infection [6]. However, such classiﬁ-
cation systems do not correspond well with the degree of malignance
and survivability [23]. A recent study showed that alterations of
tumor-related genes did notmatch the histopathologic grades in gastric
adenocarcinomas [5]. Furthermore, the levels of pathological differenti-
ation are barely consistent with the prognosis ones [5,24]. The lack of a
well-established grading system for gastric cancer remains as a major
obstacle hindering a better clinical practice in GC.
To have better GC stratiﬁcation for clinical utility, extensive efforts
have been made to classify gastric tumors based on gene expression
proﬁling. Manish et al. [25] analyzed gene expression proﬁling of gastric
adenocarcinoma samples from36 individual primary tumors and devel-
oped a 785-gene signature to classify gastric cancer [25]. Based on epi-
demiologic, histopathologic, anatomic, and molecular evidence, they
classiﬁed gastric cancer into 3 subtypes—proximal non-diffuse, diffuse,
and distal non-diffuse gastric cancer. An independent study shows
that more than 85% of the samples were classiﬁed correctly by the
785-gene signature. The diagnostic potential of thismolecular classiﬁca-
tion was further improved by using histopathologic, anatomic, and epi-
demiologic information.
Moreover, gene expression proﬁling can be utilized for the develop-
ment of response to treatments. Based on the gene expression proﬁling
data from 37 GC cell lines, Tan et al. derived a signature of 171 genes to
predict two major intrinsic genomic subtypes, G-INT, and G-DIF [26].
The G-INT cell lines were signiﬁcantly more sensitive to 5-ﬂuorouracil
and oxaliplatin but more resistant to cisplatin than the G-DIF cell lines.
In a subsequent study, Zheng et al. identiﬁed gene expression patterns
to validate three subtypes of gastric adenocarcinoma (proliferative,
metabolic, and mesenchymal) [15]. Further, other levels of cancer ge-
nome features, such as genomic instability, TP53 mutations, and DNA
hypomethylation, have been found in the tumors of the proliferativeResult Reference
Patterns of gene expression alteration after exposure to
cisplatin/5-ﬂu
Wesolowski and
Ramaswamy[62]
Offered gene information with acquired resistance Kang et al. [65]
Provided biomarkers for 5-FU sensitivity/resistance Park et al. [37]
Gave information regarding chemoresistance factors Suganuma et al. [38]
Predicted responses to 5-ﬂu Ahn et al. [66]
39-gene signature with 5-FU resistance Szoke et al. [67]
Distinguished chemosensitive state from the refractory
state
Kim et al. [39]
Provided new markers for resistance to paclitaxel Murakami et al. [68]
constructed proﬁles of resistance against each
chemotherapy agent
Gyorffy et al. [69]
Established a sensitivity database for JFCR-4andatabase
of the EGF
Nakatsu et al. [34]
Developed prediction models of the 8 anticancer drugs Tanaka et al. [33]
Acted as markers for chemosensitivity in chemo-naive
GC patients
Jung et al. [35]
Predicted the response of GC to doxorubicin Hao et al. [70]
MRP4 is a DDP resistance candidate gene Yan-Hong et al. [71]
Enhanced chemosensitivity to paclitaxel in the treatment Itsuro et al. [72]
Vorinostat improved the outcomes of GC patients Soﬁe et al. [73]
Metformin inhibited GC cell and proliferation Kiyohito et al. [74]
Table 3
Descriptions of signatures used for a systematic comparison in Table 4.
Signature Size Description
CGH_Prog [50] 70 Prognosis signature of array CGH probes
DIF [15] 78 Expression signature of diffused type
G_DIF [26] 79 Diffusion type signature
MES [15] 89 Mesenchymal signature
G_INT [24] 91 Gastric intestine signature
INT [15] 91 Intestine signature
FU [35,38,39,52] 131 5 Fu response signature
CDDP [35,38,39,52] 224 Cisplatin response signature
GA_NOR [50] 264 Gastric adenoma signature
AGC_NOR [11] 309 Advanced gastric cancer signature
MET_au [15] 315 Metabolic signature–Australia
GC_NOR [50] 364 Gastric carcinoma signature
CDDPFU [35,38,39,52] 444 5 Fu and cisplatin response signature
AGC_Mut [83,84] 446 Advanced gastric cancer mutation signature
MET_sg [15] 736 Metabolic signature–Singapore
EGC_NOR [11] 815 Early gastric cancer
PRO_au [15] 854 Proliferative signature–Australia
EGC_Mut [85] 857 Early gastric cancer mutation signature
MES_au [15] 1398 Mesenchymal signature–Australia
PRO_sg [15] 2244 Proliferative signature–Singapore
MES_sg [15] 2920 Mesenchymal signature–Singapore
Abbreviations and source literatures are listed in the ﬁrst column of the table.
Table 2
Gene expression proﬁling for GC prognosis.
Signature Data set Results Reference
Three oncogenic pathways 25 GC cell lines of discover set and 300 cases of validation set 3 oncogenic pathway combinations predicted
clinical prognosis
Ooi et al. [75]
Two genomic subtypes
(G-INT and G-DIF)
37 GC cell lines of discover set and 521 cases of validation set Associated with patient survival and response
to chemotherapy
Tan et al. [26]
98 genes 40 cases of discover set and 19 cases of validation set Predicted the overall survival Yamada et al. [45]
Eight genes Seven cases and four cases control Had a predictive role in survival of metastatic patients Lo Nigro et al. [46]
82 genes signature 30 pairs of gastric mucosa and cancer Reﬂected the genetic information for hazard rate
of recurrence
Kim and Rha [50]
Five genes 33 cases of discover set and 125 cases of validation set Independent prognostic factors for overall survival Wang et al. [47]
Four genes 48 cases Predicted surgery-related survival Xu et al. [76]
Six genes 65 cases of discover set and 96 cases of validation set Predicted the likelihood of relapse after curative resection Cho et al. [49]
Two genes Seven cases recurrence and four cases without recurrence Acted as new prognostic biomarkers in predicting
recurrence risk
Yan et al. [77]
hsa-miR-335 74 cases of discover set and 64 cases of validation set Had the potential to recognize the recurrence risk Yan et al. [78]
Three miRs 45 cases Predicted of recurrence of GC Brenner et al. [79]
Two miRs 65 cases of discover set and 57 cases of validation set As a predictor of disease progression Zhang et al. [80]
Five microRNA 164 cases and 127 normal control Expression levels of miRNAs indicated tumor
progression stages
Kim and Chung [81]
CD26 32 cases of GIST Played an important role in the progression of GISTs
and serve as a therapeutic target
Yamaguchi et al. [82]
CCL18 90 cases of discover set and 59 cases of validation set As an independent prognostic indicator Leung et al. [83]
Three genes 18 cases of discover set and 40 cases of validation set Predicted surgery-related outcome Chen et al. [84]
22 genes 56 cases of discover set and 85 cases of validation set Be useful in prospective prediction of peritoneal relapse Takeno et al. [48]
CD9 senveGISTs of discover set and 117 GISTs of validation set As potent prognostic markers in GIST Setoguchi et al. [85]
29 genes 60 cases of discover set and 20 cases of validation set Improved the prediction of recurrence in patients Chen et al. [84]
451X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458subtype. Cancer cells of the metabolic subtype are more sensitive to 5-
ﬂuorouracil than the other subtypes. Meanwhile, tumors of the mesen-
chymal subtype contain cells with characteristics of cancer stem cells
and are particularly sensitive to phosphatidylinositol 3-kinase-AKT-
mechanistic target of rapamycin inhibitors (PI3K-AKT-mTOR). It is
very likely that this approach holds a promise toward personalized
treatment.
4. Molecular prediction of TNM staging
The lymph node status (N classiﬁcation) is a strong predictor of the
outcome, and lymph node metastases usually lead to poor prognosis.
However, how to predict lymph node metastasis from primary tumor
is almost impossible using only pathological data. Gene expression pro-
ﬁling data have been utilized for this purpose.
Ken et al. developed a 92-gene signature to stratify patients with
lymph node metastasis and they achieved an accuracy of 92% [27].
These genetic signatures for predicting the lymph node status can
help surgeons select patients who may beneﬁt from extended lymph
node dissection. Clinica et al. screened primary gastric cancer gene ex-
pression proﬁles to decide whether extended lymph node dissection is
necessary [28]. In this study, gene expression was ﬁrst measured in fro-
zen tumor samples obtained from 32 patients with primary gastric ade-
nocarcinomas and then a 136 gene signature was identiﬁed to predict
lymph node status. The exceptional performance (96.8% prediction ac-
curacy) suggests that this approach can be used to tailor the extent of
lymph node dissection on an individual patient basis. Cui et al. analyzed
54 pairs ofmatched cancer and adjacent reference tissues and identiﬁed
gene expression signatures for predicting cancer grades and stages [27].
Speciﬁcally, a 10-gene signature was identiﬁed to predict early stage
(stage I + II) with an accuracy of 90% and a 9-gene signature was de-
ﬁned to predict advanced stage cancer (stage III + IV) with an accuracy
of 84%.
Moreover, gene expression-based prediction on survival can have a
better performance than TNM staging. Zhang et al. reported a similar re-
sult based on a microarray study of 72 GC samples [29]. These samples
were divided into two sets, a training set with 39 samples and a valida-
tion set with 33 samples. A panel of ten genes was identiﬁed in the
training set as a prognosticmarker thatwas correlated to overall surviv-
al and further veriﬁed in the validation set. Compared with thetraditional TNM staging system, this ten-gene prognostic marker
showed consistent prognosis results and thus was complementary to
the current staging system.
5. Molecular prediction of response to chemotherapy
Gene expression can also be used to predictwhether a GC patient re-
sponds to certain therapies. Such approaches would help provide addi-
tional predictive information for personalized treatment. Pathologic
complete response to chemotherapy indicates that some tumors are ex-
tremely sensitive to chemotherapy [30]. However, it remains extremely
challenging to predict chemotherapy sensitivity based on histopatho-
logical data. Several microarray assays have been developed for this
purpose (Table 1).
At the early genome expression proﬁling stage, it has been shown
that chemotherapy-sensitive tumors have signiﬁcantly different gene
Table 4
Overlap between the gene signatures speciﬁed in Table 3. The diagonal of thematrix below represent the number of genes in each signature. The elements in the upper-right panel represent the number of genes shared by two signatureswhile those
in the lower-left panel represent the corresponding p values computed based on the hypergeometric test.
FET P\# CGH Prog AGC Mut EGC Mut AGC NOR EGC NOR CDDP CDDPFU FU G DIF G INT GA NOR GC NOR DIF INT MES MES au MES sg MET au MET sg PRO au PRO sg
CGH Prog 70 0 6 1 3 2 2 0 0 0 2 2 1 1 1 12 18 0 2 5 9
AGC Mut 0.78 446 71 12 21 4 7 6 0 0 4 6 3 2 4 53 108 5 10 38 55
EGC Mut 0.02 7.20E–24 857 12 31 14 13 8 0 0 13 20 3 3 1 97 167 8 23 39 82
AGC NOR 0.28 0.02 0.5 309 40 2 4 8 0 0 15 40 6 11 4 72 99 21 43 15 48
EGC NOR 0.29 0.15 0.62 6.20E–12 815 1.80E+01 3.20E+01 12 0 0 41 52 2 9 4 111 162 57 62 148 222
CDDP 0.04 0.52 0.04 0.64 1.20E–03 224 12 15 0 0 4 2 0 0 3 9 30 0 4 29 47
CDDPFU 0.19 0.73 0.87 0.79 3.00E–04 1.00E–03 444 10 0 0 15 13 4 3 1 18 34 7 12 40 105
FU 0.36 0.02 0.09 1.40E–04 1.80E–03 7.70E–13 1.10E–04 131 0 0 4 11 1 1 1 14 31 3 5 20 36
G DIF 0.23 0.82 0.96 0.69 0.96 0.57 0.82 0.39 79 0 0 0 0 0 0 0 0 0 0 0 0
G INT 0.26 0.86 0.98 0.74 0.97 0.62 0.86 0.44 0.29 91 0 0 0 1 0 0 0 0 0 0 0
GA NOR 0.06 0.66 0.19 2.10E–06 6.30E–15 0.15 1.70E–04 0.03 0.63 0.69 264 149 0 7 2 26 42 34 47 12 37
GC NOR 0.12 0.66 0.07 2.40E–24 8.60E–17 0.75 0.02 3.10E–06 0.75 0.8 9.80E–204 364 3 9 1 38 57 60 72 21 57
DIF 0.03 0.08 0.4 0.00015 0.59 0.57 0.02 0.09 0.26 0.29 0.63 0.05 78 0 1 42 54 0 0 5 5
INT 0.04 0.31 0.51 9.30E–09 2.80E–03 0.62 0.13 0.11 0.29 0.06 1.90E–05 4.00E–06 0.29 91 0 0 2 18 29 2 37
MES 0.04 0.04 0.88 0.01 0.26 0.02 0.56 0.11 0.29 0.32 0.1 0.46 0.04 0.32 89 17 37 1 7 5 3
MES au 6.40E–04 1.50E–05 9.30E–08 6.00E–22 1.30E–13 0.94 0.99 0.03 1 1 0.02 2.30E–03 2.50E–30 1 1.90E–05 1400 1360 0 6 7 12
MES sg 2.60E–03 1.40E–09 1.60E–06 6.20E–17 6.50E–07 0.54 1 8.70E–04 1 1 0.15 0.15 6.00E–30 1 3.00E–11 0 2920 5 14 30 44
MET au 0.65 0.66 0.9 1.90E–09 2.20E–23 0.97 0.35 0.14 0.7 0.75 5.40E–23 4.90E–46 0.69 8.80E–17 0.39 1 1 315 199 1 27
MET sg 0.45 0.92 0.9 2.30E–15 3.60E–09 0.9 0.78 0.31 0.94 0.96 3.80E–21 1.30E–34 0.94 1.60E–21 0.01 1 1 3.30E–217 736 8 60
PRO au 0.06 6.50E–06 0.2 0.19 8.30E–57 1.00E–08 9.60E–07 7.40E–08 0.96 0.98 0.28 0.04 0.1 0.72 0.15 1 1 1 1 854 715
PRO sg 0.21 0.11 0.85 3.20E–03 4.20E–42 1.90E–06 8.30E–16 2.00E–08 1 1 0.04 1.30E–03 0.85 1.90E–14 0.99 1 1 0.87 0.99 0 2240
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453X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458expression than that from chemotherapy-resistant cases [31,32]. Tana-
ka et al. analyzed a microarray data from 19 cancer cell lines, including
2 GC cell lines, and developed a 12-gene signature to predict the re-
sponse to 8 drugs (5-FU, CDDP, MMC,DOX, CPT-11, SN-38, TXL, and
TXT) [33]. The signatures have the power to predict accurately not
only the in vitro efﬁcacy of the drugs but also GC patients' response in-
cluding survival, time to treatment failure, and tumor growth to 5-FU.
Nakatsu et al. established a panel of 45 human cancer cell lines (JFCR-
45), including 12 stomach cancer cell lines [34]. They assessed the
chemosensitivity of JFCR-45 to 53 anticancer drugs by growth inhibition
experiments and built up a sensitivity database for JFCR-45 to antican-
cer drugs. Using these databases, they have identiﬁed gene signatures
that can predict chemosensitivity of gastric cancer. Jung et al. developed
G-matrix (gene expression database) and C-matrix (chemosensitivity
database) from 13 gastric cancer cell lines treated with 16 anticancer
agents using 22 K human oligo chips and identiﬁed an 85-gene signa-
ture be associated with chemosensitivity of gastric cancer with respect
to the major anticancer drugs [35]. Recently, Ivanova et al. generated a
comprehensive cohort including mRNA expression, DNA methylation,
and cisplatin response data from 20 gastric cancer cell lines [36]. A
panel of 291 genes was found to be differently expressed between the
top four cell lines most sensitive to cisplatin and those most resistant
lines. Notably, BMP4 was overexpressed in the cisplatin-resistant cellFig. 2. Clustering analysis of gene sets based on the signiﬁcance level of overlap between signatu
signatures was determined by lg(p value), where p value was based on the hypergeometric telines. Furthermore, BMP4 expression was signiﬁcantly up-regulated
(P= 4.53 × 10−5; 2.25-fold enrichment) in 197 gastric cancer samples
when comparedwith non-malignant gastric tissues. In primary tumors,
BMP4 promoter methylation levels were inversely correlated with
BMP4 expression, and GC patients with high BMP4 expression in
tumor exhibited signiﬁcantly worse prognosis. These results suggested
that BMP4 epigenetic and expression status may represent promising
biomarkers for GC cisplatin sensitivity.
Themajor cause of treatment failure for GC is the development of ac-
quired resistance to chemotherapy. Gene expression signatures can be
used to identify subgroups thatwill acquire resistance to chemotherapy.
Such a strategy would provide additional predictive information for in-
dividualized treatment. Park et al. analyzed genes expression proﬁling
of 5-FU sensitive and/or resistant GC cell lines [37]. A 13-gene signature
was identiﬁed to predict response to 5-FU. Suganuma et al. identiﬁed a
23-gene signature for DDP resistance (cisplatin-resistance) by compar-
ing the gene expression in 22 pairs of DDP-resistant tumor samples and
surrounding normal tissues [38]. Similarly, Kim et al. compared the ex-
pression proﬁles from gastric cancer biopsy specimens obtained at a
chemosensitive state with those obtained at a refractory state and iden-
tiﬁed 119 genes associated with acquired resistance to 5-FU/Cisplatin
[39]. In another study, Kim et al. compared the gene expression proﬁling
of 22 pre-CF (cisplatin and ﬂuorouracil)-treated samples with that ofres. Details about the signatures can be found in Table 3. The similarity between two genes
st.
454 X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458the matched post-CF-treated samples and identiﬁed 72 differentially
expressed genes as a signature for acquired resistance [40]. The 72-
gene signature was an independent predictor for the time to progres-
sion and survival. In a similar study, they analyzed 90 gastric cancer
patient samples and 34 healthy volunteers' samples using microRNA
gene proﬁling. In total, 82 sampleswere used as a training set to discov-
er candidate markers correlated to chemotherapy response, and 8
samples were used for validation. Fifty-eight microRNAs were found
to be capable of discriminating patients who are likely or unlikely to
respond favorably to CF therapy, suggesting that such a microRNA
predictor can provide a useful guidance for personalized chemotherapy
[41]. Taken together, genomic signatures derived from gene expression
prooﬁng have the capacity to connect clinical intervention especially
in predicting sensitivity and resistance to speciﬁc chemotherapy
regimens.Table 5
Integrative gastric subtyping studies including The Cancer Genome Atlas (TCGA), the Asia
Cancer Research Group (ACRG), and diffusion gastric adenocarcinoma (DGC).
System Molecular
subtypes
Sample
size
Percentage Reference
TCGA 295
EBV positive 8.81 TCGA [58]
MSI high 21.69
GS 19.66
CIN 49.83
ACRG 300 Cristescu et al. [59]
MSS/TP53+ 35.70
MSS/TP53− 26.30
MSS/EMT 15.30
MSI 22.70
genomic alteration Deng et al. [86]
FGFR2 9.00
KRAS 9.00
EGFR 8.00
ERBB2 7.00
MET 37.00
DGC-RHOA-Japan 98 Wang [87]
RHOA+ 14.70
RHOA− 85.30
DGC-RHOA-HKU 87
RHOA+ 25.3 Kakiuchi [88]
RHOA− 74.7
Mutation signature 49 Wong et al. [87]
TpT 36.73
CpG NA
TpCp[A/T] NA6. Molecular prognosis of GC
Another important function of GC Gene expression proﬁling is to
predict which gastric cancer patients have good or poor clinical out-
comes (Table 2). Many studies have shown that gene expression signa-
tures can classify tumors into intrinsic subtypes and predict the survival
of GC patients [26]. Several genomic studies also show that gene expres-
sion proﬁling can predict patients with a high risk for recurrence and
thus can potentially improve clinical practice [42–44]. Now it is evident
that gene expression techniques may signiﬁcantly improve our ability
to predict the risk of recurrence and to tailor the treatment for each in-
dividual gastric cancer patient.
Gene expression data in tandem with clinical information have
made it possible to construct the predictive models for the outcome of
gastric cancer. Yamada et al. analyzed 40 endoscopic biopsy GC samples
to identify a 98-gene signature that are signiﬁcantly correlatedwith the
overall survival [45]. In particular, PDCD6was identiﬁed as a prognostic
biomarker of GC through a multivariate analysis. Lo Nigro et al. com-
pared gene expression proﬁling of 3 long-term survival cases withmet-
astatic gastric cancer with that of 4 normal cases [46]. An 8-gene
signature was identiﬁed to distinguish long survivors from the control
cases. Wang et al. collected 158 gastric cancer patients, among which
33 caseswere used as a training set and 125 cases for RT-PCR as a testing
set [47]. A 5-gene signature was established for clinical and prognostic.
Recurrence and metastasis are the main causes for the death of GC
patients. Genomic signatures have successfully been used to predict
the relapse of GC. Peritoneal relapse is the most common pattern of
tumor progression in advanced gastric cancer. Clinicopathological ﬁnd-
ings are often inadequate for predicting peritoneal relapse. Takeno et al.
compared gene expression proﬁles of 38 relapse-free GC patients with
those from 18 peritoneal relapse ones and developed a 22-gene signa-
ture to predict peritoneal relapse with an accuracy of 68% [48]. Cho
also analyzed 65 gastric adenocarcinoma tissues and developed a risk
score based on 6 genes to predict relapse of GC. This risk score was suc-
cessfully tested in an independent cohort [49].
To establish prognostic index (PI) for each patient that reﬂects the
genetic information, Kim et al. analyzed 30 pairs of gastric tumors and
normal gastric tissues to develop genetic alteration score (GAS) for esti-
mating patient's survival time by the cDNAmicroarray-based CGH [50].
GAS was based on 82 genes, and the prediction accuracy for recurrence
was 83.33%. GAS was able to capture important genetic information for
hazard rate of recurrence and distinguish a patient's recurrence status,
survival status, and cancer stage status.
The development of predictivemolecularmodels for GC treatment is
still at an early stage, and thosemodels need some substantial improve-
ment for the use in clinical trials. High-quality studies should be con-
ducted to develop accurate, reliable, and reproducible models for
clinical practice. Only then will it be possible to use predictive models
routinely to tailor GC treatment.7. Comparison of predictive gene signatures in GC
Most genomic signatureswere derived fromdata sets with a relative
small sample size, raising the issue of reproducibility, especially when
considering the heterogeneity nature of cancer. To examine whether
those signatures are sample dependent or study speciﬁc, we systemati-
cally compared 21 gene signatures predictive of GC stages, chemother-
apy response, andmetastasis from 9 studies. These gene signatures had
at least 70 genes and were derived from a relative larger sample popu-
lation. Such selection criteria enable meaningful enrichment test.
As shown in Table 3, nine of the 21 signatures were from a recent
study of GC subtypes with different responses to PI3-kinase inhibitors
and 5-ﬂuorouracil [15]. The signatures identiﬁed by Lei et al. [15] are
themost comprehensive and signiﬁcantly overlap with at least one sig-
nature in 7 of the other 8 studies. In this study, a cohort of 248 cases
from Singapore (SG) were employed as discovering data set, with an-
other cohort of 201 cases from Singapore and 70 cases from Australia
(AU) for validation. Intriguingly, based on clinical traits, including
Lauren's classiﬁcation, stage of disease, a more detailed system can be
obtained, involving DIF (diffused signature), INT (intestine signature),
MET-sg (metabolic signature–Singapore), MET-au (metabolic signa-
ture–Australia), MES-sg (mesenchymal signature–Singapore), MES-au
(mesenchymal signature–Australia), PRO-sg (proliferative signature–
Singapore), and PRO-au (proliferative signature–Australia).
Table 4 and Fig. 2 show theoverlaps between these signatures. To as-
sess the statistical signiﬁcance of an overlap between two differentially
expressed gene signatures, we used the standard Fisher's exact test
(FET) [51]. The INT signature signiﬁcantly overlaps with MET-au and
MET-sg, with FET P b 1.6E−21 and P b 8.8E−17, respectively. In con-
trast, the DIF signature overlaps more signiﬁcantly with MES-sg and
MES-au with FET P b 6.0E−30 and P b 2.5E−30, respectively, consis-
tent to canonical Lauren's classiﬁcation. The signature EGC_NOR (early
gastric cancer signature) [12] highly overlaps with the proliferative sig-
natures PRO_sg and PRO_au [15] with FET P b 4.2E−42 and 8.3E−57,
respectively. Meanwhile, the signature AGC_NOR (advanced gastric
cancer signature) is enriched in the MET signatures from the
Singapore and Australia data sets [15] with FET P b 6.2E−17 and
6.0E−22, respectively, indicating the validity of this molecular subtype
455X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458method.Moreover, the signature PRO_au [15]moderately overlapswith
those chemotherapy response signatures, CDDP, CDDPFU, and FU [35,
38,39,52] with FET P b 1.0E−8, 9.6E−7, and 7.4E−8, respectively, albe-
it with unknownmechanism. Interestingly, the signature EGC_NOR [12]
signiﬁcantly overlaps with GA_NOR [53] with FET P b 6.3E−15, and
they share some important genes such as RBP2, FHL1, and NME1. RBP2
was found to be overexpressed in GC and plays some key roles in the
process of gastric carcinogenesis [54,55]. FHL1, a tumor suppressor
gene, is involved in migration, invasion, and growth in GC due to a
loss-of-functionmutation [56,57]. In summary, these signatures can im-
prove our understanding the processes frombenign tumor tomalignant
tumor of stomach.
8. Integrated genomic subtyping of GC
The large-scalemolecular proﬁling data in GC at The Cancer Genome
Atlas (TCGA) provide an excellent opportunity to develop advanced
molecular classiﬁers and predictors for GC diagnosis and treatments.Fig. 3. Enrichment ofMSigDB and gastric speciﬁc gene sets in theGC gene signatures. The c2 and
enrichment of the analysis of gene sets listed in Table 3.Based on the TCGA data in GC, four major molecular subtypes of GC
were deﬁned, and they include EBV-infected tumors, MSI tumors,
genomically stable tumors, and chromosomally unstable tumors. The
molecular classiﬁcation not only serves as a valuable adjunct to histopa-
thology but also shows distinct salient genomic features providing a
guide to targeted agents [58].
Recently, Cristescu et al. analyzed gene expression data of 300
primary gastric tumors to establish four molecular subtypes linked to
distinct patterns ofmolecular alterations, disease progression, andprog-
nosis, which includedMSS/EMT subtype, MSI subtype, MSS/TP53+ sub-
type, and MSS/TP53− subtype [59]. The MSS/EMT subtype includes
diffuse-subtype tumors with the worst prognosis, the tendency to
occur at an earlier age and the highest recurrence frequency (63%) of
the four subtypes. MSI subtype contains hyper-mutated intestinal-
subtype tumors occurring in the antrum, the best overall prognosis,
and the lowest frequency of recurrence (22%) among the four subtypes.
Patients of MSS/TP53+ and MSS/TP53− subtypes have intermediate
prognosis and recurrence rates, while the TP53-active group showsc5 sets include biological processes and KEGG fromMSigDBversion 5.0were employed for
456 X. Lin et al. / Computational and Structural Biotechnology Journal 13 (2015) 448–458better prognosis. They also validated these subtypes in independent co-
horts and showed that the four molecular subtypes were associated
with not only recurrence pattern and prognosis but also distinct pat-
terns of genomic alterations. These subtypes can provide a molecular
subtyping framework for preclinical, clinical, and translational studies
of GC.
Whole genomic sequencing has the capacity to deﬁne subtyping of
GC at the DNA level. We summarized the recent advances in this direc-
tion in Table 5. Thesemutation signatures are anticipated to open a new
avenue for targeted GC therapy.
9. Biological functions underlying gene signatures in GC
Gene signatures derived from gene expression proﬁling of tumor
samples not only allow us to stratify GC cases as classiﬁer but also en-
able us a better understanding of the underlying biological process
and molecular pathways. Thus, we further examined the enrichment
of gene signatures by intersecting these signatures with those gene
sets listed in the MSigDB database [60].
The c2 and c5 sets in MSigDB version 5.0, including biological pro-
cesses and KEGG pathways, respectively, were tested for enrichment
in the gene signatures listed in Table 3. The result was represented by
the heat map in Fig. 3. Many cancer-associated molecular pathways
have been captured in terms of highly overlapped with GC gene signa-
tures. Notably, the digestion and pyrimidine signaling pathways highly
enriched inmany signatures, indicating they are GC speciﬁc and related
to inﬂammation.
10. Summary and prospective
The ﬁndings from the analysis of gene expression data in GC has a
signiﬁcant impact on our understanding of GC biology by bringing the
concept of the heterogeneity of GC to the forefront of GC research and
clinical practice [8]. Gene expression proﬁling technology will enable
clinicians not only to estimate the likelihood that certain therapies
will be beneﬁcial but also to determine when and how to modify treat-
ment options.More informeddecisionmakingwill ultimately enable in-
creased rates of response and survival [9,15,26,40,47]. High-throughput
molecular techniques will not replace conventional clinical and patho-
logical evaluation to classify GC but rather serve as an adjunct to
known clinical methods.
Many gene signatures have been developed, but there is little over-
lap between those gene lists, and the reproducibility is usually very poor
[8]. The poor reproducibility of these models is due to many intrinsic
problems associated with heterogeneity in patient populations and tu-
mors and microarray-based approaches. First, patient populations and
treatments are diversiﬁed: different patient demographics and varied
treatment regimens lead to variations into predictive classiﬁers. Distri-
butions of age, race, and gender have a signiﬁcant impact on molecular
proﬁling [8]. Therefore, it is difﬁcult to compare expression data from
different treatment plans, and such inconsistency limits our ability to
develop robust predictive molecular models. Second, the selection of
samples is not consistent. Tumors vary in their composition and are
highly heterogeneous for stromal and cancerous components. Micro-
dissection is often used to ensure that a pure tumor cell population
can be proﬁled. Intriguingly, stromal signatures have been shown to
be informative for predicting chemo sensitivity, recurrence, and out-
come [61]. Third, there are different proﬁling platforms and statistical
analysis approaches. Biases in proﬁling platforms and analytic ap-
proaches further complicate the reproducibility. Therefore, it is essential
that studies are designed and carried out thoughtfully to gain the most
appropriate and relevant information. Fourth, there lacks large-scale in-
dependent validation. While many studies have used molecular proﬁl-
ing data to develop predictors for predicting treatment response and
prognosis in GC, those models share a very limited number of genes.Thus, reliability and reproducibility ofmicroarray data remain question-
able unless their performance is conﬁrmed at a relatively large scale.
Recently, several gene microarray-based tools have been commer-
cially developed for clinical use in breast cancer [62,63]. Now the clinical
practice of predictive arrays in gastric cancer is falling behind relative to
breast cancer. A lot of factors contribute to this lag-behind, but perhaps
the ﬁrst and foremost is the drastically greater volume of research into
predictive medicine in breast cancer [63]. Comparing to breast cancer,
there are much less common and ongoing controversies in optional
multimodality therapy in GC [52]. With more advanced technologies
and expanding knowledge from a multitude of existing studies, more
accurate subtypes of GC are likely to be teased out from the existing
groups. Better characterization of genetic subtypes of gastric cancer
may reduce the biological variation and allow the generation of more
robust predictive signatures for individual tumor subtypes. Only then
will it be possible to apply predictive genomics to clinical practice.
The development and improvement of gene expression assays have
led to some major breakthroughs in GC research, which will have the
potential to inﬂuence the clinical treatment of patients. Although
there are signiﬁcant challenges in implementing genomic medicine in
GC [8,64], the future genomic medicine will dramatically reshape how
the disease is characterized and deﬁned, how medicine is managed to
patients, and how patients are given tailored therapies. The large-scale
molecular proﬁling data in GC at The Cancer Genome Atlas (TCGA) pro-
vide an excellent opportunity to develop advancedmolecular classiﬁers
and predictors for GC diagnosis and treatment.
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